Psilocybin-Assisted Therapy

The Minnesota Psychedelic Medicine Task Force (PMTF) is making strides toward finalizing a set of recommendations on how the state might regulate psychedelic substances, including psilocybin, MDMA and LSD. According to Marijuana Moment, the group has already approved the creation of a state-...

Sam Altman, co-founder of OpenAI and the visionary behind ChatGPT, recently opened up about his transformative experiences with psychedelics in his appearance on the podcast Life in Seven Songs. The tech executive shared personal anecdotes about how psychedelic experiences profoundly impacted his...

Psyence Biomedical Ltd (NASDAQ:PBM) recently announced that its wholly-owned subsidiary, Psyence Australia (Pty) received full approval from the Australian Health Research Ethics Committee (HREC) to initiate its planned Phase IIb study in Melbourne, Australia. The study will examine the use of...

Psilocybin-assisted therapy has hit a milestone as clinical trial results show potential benefits for Generalized Anxiety Disorder (GAD.)  With variable symptoms, the condition typically involves a person suffering from excessive anxiety and worry for over six months, potentially causing...

A majority of Canadians (79.3% ) consider psilocybin-assisted therapy as "a reasonable medical choice" for addressing "existential distress" during the final stages of life, a team of 12 experts behind the new research revealed. The study, published last month in the journal Palliative Care, is...

Starting this October, scientists at Imperial College London’s (ICL) Centre for Psychedelic Research will assess psilocybin-assisted therapy for gambling addiction, noted Psychedelic Spotlight.  Government-funded, the study will focus on understanding brain function in the gambling...

The peer-reviewed journal Psychology of Addictive Behaviors published by the American Psychological Association (APA) released a new analysis by Fluence, NYU and UC-SF of a clinical trial of psilocybin-assisted psychotherapy for the treatment of Alcohol Use Disorder (AUD.)  What triggered...

Positive long-term follow-up data from Sunstone Therapies’ investigator-initiated Phase 2 study assessing COMPASS Pathways’ (NASDAQ: CMPS) synthetic psilocybin COMP360 paired with psychological support in cancer patients with Major Depressive Disorder (MDD) is out. 57% of patients...

After Washington Gov. Jay Inslee greenlighted SB 5263 creating a pilot program for psilocybin therapy led by the University of Washington's School of Medicine is preparing to begin treatment on Jan. 1, 2025. Based in Seattle, the mandated clinical trial will recruit...

Health-Canada licensed psychedelics biotech Lucy Scientific Discovery (NASDAQ: LSDI) and not-for-profit psilocybin advocate organization TheraPsil have partnered toward advancing medical psilocybin access and research. Since 2019, TheraPsil has worked on lawful and compassionate access to...

The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started recruiting participants for the first-ever clinical trial assessing the effects of psilocybin in adults diagnosed with Fragile X Syndrome (FXS), the leading genetic...

The Canadian biopharma company advancing at-home psilocybin microdose studies and supporting Veteran patients, Apex Labs Ltd., has received Health Canada’s approval for a comprehensive, “statistically powered” macro-and-multi dose advanced psilocybin trial on 160 patients. ...

Results from an advanced clinical trial assessing psilocybin-assisted therapy for patients with cancer and Major Depressive Disorder (MDD) conducted by oncology center Sunstone Therapies were published in the acclaimed JAMA Oncology. The open-label Phase 2 study tested psilocybin paired with ...

Calgary-based SABI Mind is the first clinical site to receive approval from the Health Research Ethics Board of Alberta (HREBA) to launch a trial assessing psilocybin-assisted psychotherapy for the treatment of Alcohol Use Disorder (AUD). Sponsored by Canadian biotech company Clairvoyant...

As of July 1, psilocybin and MDMA (and related substances to both) can now be prescribed by authorized psychiatrists in Australia, which has become the fourth government agency to enact a compassionate use program for psychedelic-assisted therapies to treat mental health conditions joining Israel,...